Phenominer Database Results (249 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Average Type Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
GK/MolTac diastolic blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. arterial blood pressure trait male 112 days 8 93.0 mmHg 5.0 14.14 vascular transducer tipped catheter 0.0 0 102959 2783
GK/MolTac arterial elastance control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 1.26 null 0.12 0.34 vascular transducer tipped catheter 0.0 0 102973 2783
GK/MolTac stroke index control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 0.2 ul/g 0.04 0.11 vascular transducer tipped catheter 0.0 0 102971 2783
GK/MolTac systemic vascular resistance control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. arterial blood flow trait male 112 days 8 2.49 mmHg/ml/min 0.23 0.65 vascular transducer tipped catheter 0.0 0 102975 2783
GK/MolTac red blood cell count rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 7 8.3 x 10E6 cells/ul 0.23 0.6 automated blood cell counting method 0.0 0 103844 2864
GK/MolTac red blood cell count rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 6 8.9 x 10E6 cells/ul 0.08 0.2 automated blood cell counting method 0.0 0 103843 2864
GK/MolTac red blood cell count rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 7 9.8 x 10E6 cells/ul 0.04 0.1 automated blood cell counting method 0.0 0 103850 2864
GK/MolTac blood hemoglobin level sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 7 16.1 g/dl 0.64 1.7 automated hematology analysis 0.0 0 103854 2864
GK/MolTac blood hemoglobin level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 5 16.7 g/dl 0.72 1.6 automated hematology analysis 0.0 0 103861 2864
GK/MolTac blood hemoglobin A1c level sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 7 5.19 % 0.05 0.14 automated hematology analysis 0.0 0 103878 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 7 5.19 % 0.08 0.2 automated hematology analysis 0.0 0 103883 2864
GK/MolTac blood glucose level sodium chloride solution (for 23 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 95 days-102 days 4 168.0 mg/dl 9.0 18.0 oral glucose tolerance test 0.0 0 103805 2864
GK/MolTac blood glucose level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 122 days-129 days 4 145.0 mg/dl 7.5 15.0 oral glucose tolerance test 0.0 0 103810 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 3 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103820 2864
GK/MolTac whole body insulin sensitivity index rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 3 10,000/√(FG x FI) x (Ḡ x Ī) 1.73 null 0.2 0.34 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103827 2864
GK/MolTac whole body insulin sensitivity index sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 10,000/√(FG x FI) x (Ḡ x Ī) 1.37 null 0.25 0.49 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103826 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 (fasting glucose x fasting insulin)/22.5 13.6 null 2.85 5.7 oral glucose tolerance test 7200.0 0 103833 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 (fasting glucose x fasting insulin)/22.5 14.2 null 2.15 4.3 oral glucose tolerance test 7200.0 0 103837 2864
GK/MolTac blood glucose level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 122 days-129 days 4 177.0 mg/dl 5.5 11.0 oral glucose tolerance test 0.0 0 103809 2864
GK/MolTac maximum rate of positive change in left ventricular blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 10429.0 mmHg/s 568.0 1606.55 vascular transducer tipped catheter 0.0 0 102977 2783
GK/MolTac heart left ventricle end-diastolic posterior wall index control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricle posterior wall thickness male 112 days 8 8.85 mm/kg 0.31 0.88 echocardiography 0.0 0 102992 2783
GK/MolTac body weight control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 0 389.0 g 7.0 body weighing method 0.0 0 103985 2885
GK/MolTac blood glucose level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 6 382.0 mg/dl 69.0 169.01 blood glucose analysis 0.0 0 103990 2885
GK/MolTac plasma insulin level fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 70 days-77 days 6 37.18 mU/l 3.93 9.62 oral glucose tolerance test 0.0 0 103811 2864
GK/MolTac plasma insulin level rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 34.58 mU/l 4.68 9.36 oral glucose tolerance test 0.0 0 103814 2864
GK/MolTac plasma insulin level sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 37.96 mU/l 6.5 13.0 oral glucose tolerance test 0.0 0 103815 2864
GK/MolTac plasma insulin level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 27.3 mU/l 4.16 8.32 oral glucose tolerance test 0.0 0 103817 2864
GK/MolTac blood insulin level control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 12 71.47 mU/l 8.24 28.53 blood insulin analysis 0.0 0 104003 2885
GK/MolTac blood dipeptidyl peptidase 4 activity level control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 35.0 pmol/min 14.0 blood enzyme activity assay 0.0 0 104011 2885
GK/MolTac blood malondialdehyde level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.0 umol/l 1.6 thiobarbituric acid assay 0.0 0 104018 2885
GK/MolTac plasma troponin T level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood protein amount male 112 days 8 3044.0 pg/ml 750.0 2121.32 electrochemiluminescence immunoassay 0.0 0 102935 2783
GK/MolTac plasma triglyceride level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood triglyceride amount male 112 days 8 0.68 mmol/l 0.12 0.35 automated plasma triglyceride analysis 0.0 0 102941 2783
GK/MolTac blood glucose level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 420 days 11 289.8 mg/dl 10.8 35.82 blood glucose test strip read by optical glucometer 0.0 0 fasting blood glucose, non fasting blood glucose 106907 3071
GK/MolTac A23187-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel U46619 (0.3 umol/l) then A23187 (10 umol/l) Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. vasodilation trait male 154 days 6 89.8 % 4.0 9.8 ex vivo myography 0.0 0 with video image analysis A23187-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel (CMO:0003660) 109120 3109
GK/MolTac blood glucose level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 60 days 6 144.0 mg/dl 7.2 17.64 blood glucose test strip read by optical glucometer 0.0 0 fasting blood glucose, non fasting blood glucose 106911 3071
GK/MolTac serum insulin level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 240 days 11 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106918 3071
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 10 124.2 mg/dl 7.2 22.77 oral glucose tolerance test 0.0 oral glucose 0 min 110745 3183
GK/MolTac serum amylase activity level sleeve gastrectomy (for 126 days) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 252 days 10 2149.0 U/l 52.0 164.44 automated serum analysis 0.0 105 days 110762 3183
GK/MolTac serum amylase activity level sham surgical control condition (for 126 days) then pantoprazole (100 umol/kg) (for 112 days) and sodium bicarbonate (8.5 %) (for 112 days) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 252 days 9 2164.0 U/l 29.0 87.0 automated serum analysis 0.0 91 days 110761 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 8 262.8 mg/dl 23.4 66.19 oral glucose tolerance test 0.0 oral glucose 60 min 110750 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 2 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 8 217.8 mg/dl 10.8 30.55 oral glucose tolerance test 0.0 oral glucose 120 min 110756 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 2 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 9 219.6 mg/dl 7.2 21.6 oral glucose tolerance test 0.0 oral glucose 120 min 110758 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 105 days 9 337.3 g 7.8 23.4 body weighing method 0.0 0 110731 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 112 days 8 median 124.2 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 7.4; 6.2 75%; 25% 110738 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 119 days 8 median 109.8 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 6.6; 5.7 75%; 25% 110741 3183
GK/MolTac blood glucose level control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 98 days 9 129.6 mg/dl 5.4 16.2 blood glucose analysis 0.0 0 110275 3168
GK/MolTac heart weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. heart mass female 98 days 10 0.76 g 0.02 0.05 post excision weight measurement 0.0 0 110300 3168
GK/MolTac blood glucose level control condition Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 56 days 9 120.6 mg/dl 1.8 5.4 blood glucose analysis 0.0 0 110263 3168
GK/MolTac tissue mitochondrial DNA to nuclear DNA ratio running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. tissue DNA amount male 147 days 6 638.9 null 173.5 424.99 real-time polymerase chain reaction assay 0.0 0 tissue mitochondrial DNA to nuclear DNA ratio (CMO:0003889) 138275 2885
GK/MolTac plasma renin activity level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. renin activity male 112 days 8 4.8 ng/ml/h 1.9 5.37 radioimmunoassay 0.0 0 102947 2783
GK/MolTac systolic blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. arterial blood pressure trait male 112 days 8 127.0 mmHg 5.0 14.14 vascular transducer tipped catheter 0.0 0 102957 2783
GK/MolTac red blood cell count rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 5 9.0 x 10E6 cells/ul 0.22 0.5 automated blood cell counting method 0.0 0 103846 2864
GK/MolTac blood hemoglobin level rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 7 15.4 g/dl 0.45 1.2 automated hematology analysis 0.0 0 103856 2864
GK/MolTac blood hemoglobin level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 5 16.3 g/dl 0.54 1.2 automated hematology analysis 0.0 0 103858 2864
GK/MolTac hematocrit control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 7 50.0 % 1.06 2.8 automated hematology analysis 0.0 0 103863 2864
GK/MolTac hematocrit sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 7 53.4 % 1.44 3.8 automated hematology analysis 0.0 0 103869 2864
GK/MolTac hematocrit rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 7 49.8 % 1.4 3.7 automated hematology analysis 0.0 0 103868 2864
GK/MolTac hematocrit rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 7 54.8 % 1.85 4.9 automated hematology analysis 0.0 0 103873 2864
GK/MolTac hematocrit rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 6 53.8 % 0.65 1.6 automated hematology analysis 0.0 0 103867 2864
GK/MolTac blood hemoglobin A1c level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 7 4.94 % 0.09 0.24 automated hematology analysis 0.0 0 103875 2864
GK/MolTac blood hemoglobin A1c level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 7 4.8 % 0.07 0.19 automated hematology analysis 0.0 0 103877 2864
GK/MolTac hematocrit rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 7 57.7 % 0.23 0.6 automated hematology analysis 0.0 0 103874 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 7 4.86 % 0.1 0.27 automated hematology analysis 0.0 0 103880 2864
GK/MolTac blood glucose level fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 70 days-77 days 6 209.0 mg/dl 4.9 12.0 oral glucose tolerance test 0.0 0 103804 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103823 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 70 days-77 days 6 (fasting glucose x fasting insulin)/22.5 16.2 null 1.63 4.0 oral glucose tolerance test 7200.0 0 103832 2864
GK/MolTac red blood cell count control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 7 7.2 x 10E6 cells/ul 0.3 0.8 automated blood cell counting method 0.0 0 103841 2864
GK/MolTac time constant of left ventricular pressure decay control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 8.15 ms 0.19 0.54 vascular transducer tipped catheter 0.0 0 102981 2783
GK/MolTac maximum rate of positive change in left ventricular blood pressure to left ventricular end-diastolic volume ratio control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 104.0 mmHg/s/ul 10.0 28.28 vascular transducer tipped catheter 0.0 0 102988 2783
GK/MolTac heart left ventricle weight to body weight ratio control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricle mass male 112 days 8 3.41 mg/g 0.17 0.48 echocardiography 0.0 0 102990 2783
GK/MolTac body weight running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 0 374.0 g 4.0 body weighing method 0.0 0 103984 2885
GK/MolTac body weight control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 0 389.0 g 7.0 body weighing method 0.0 0 103983 2885
GK/MolTac blood glucose level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 12 289.0 mg/dl 29.0 100.46 blood glucose analysis 0.0 0 103995 2885
GK/MolTac plasma insulin level sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 38.74 mU/l 7.28 14.56 oral glucose tolerance test 0.0 0 103812 2864
GK/MolTac plasma insulin level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 38.22 mU/l 5.2 10.4 oral glucose tolerance test 0.0 0 103816 2864
GK/MolTac blood dipeptidyl peptidase 4 activity level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 235.0 pmol/min 25.0 blood enzyme activity assay 0.0 0 104009 2885
GK/MolTac blood malondialdehyde level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.7 umol/l 1.6 thiobarbituric acid assay 0.0 0 104017 2885
GK/MolTac blood malondialdehyde level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.4 umol/l 0.9 thiobarbituric acid assay 0.0 0 104020 2885
GK/MolTac plasma NH2-terminal pro-B-type natriuretic peptide level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood protein amount male 112 days 8 3416.0 ng/l 585.0 1654.63 electrochemiluminescence immunoassay 0.0 0 plasma pro bnp 102933 2783
GK/MolTac body weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. body mass female 60 days 6 209.0 g 6.0 14.7 body weighing method 0.0 0 body weight 106893 3071
GK/MolTac food intake rate control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. eating behavior trait female 240 days 11 15.7 g/d 0.3 0.99 food intake measuring method 0.0 0 food consumption 106900 3071
GK/MolTac serum fructosamine level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood fructosamine amount female 0 days 11 253.0 umol/l 5.0 16.58 serum fructosamine analysis 0.0 0 serum fructosamine analysis 106955 3071
GK/MolTac serum insulin level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 60 days 6 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106917 3071
GK/MolTac serum insulin level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 420 days 11 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106919 3071
GK/MolTac liver wet weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. liver mass female 420 days 0 9.91 g 0.38 post excision weight measurement 0.0 0 106943 3071
GK/MolTac kidney fractional mesangial volume control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. kidney glomerulus morphology trait female 420 days 0 35.0 % 1.7 ex vivo electron microscopy with digital image analysis 0.0 0 kidney fractional mesangial volume 106949 3071
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 9 113.4 mg/dl 5.4 16.2 oral glucose tolerance test 0.0 oral glucose 0 min 110746 3183
GK/MolTac heart weight control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. heart mass male 154 days 0 1.39 g 0.06 post excision weight measurement 0.0 0 108029 3109
GK/MolTac mean arterial blood pressure control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. arterial blood pressure trait male 112 days 0 118.0 mmHg 1.0 tail cuff plethysmography 0.0 0 108031 3109
GK/MolTac blood glucose level control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. blood glucose amount male 112 days 0 190.8 mg/dl 7.2 blood glucose test strip read by electrochemical glucometer 0.0 0 108035 3109
GK/MolTac blood glucose level control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. blood glucose amount male 154 days 0 165.6 mg/dl 34.2 blood glucose test strip read by electrochemical glucometer 0.0 0 108037 3109
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 0.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 9 289.8 mg/dl 12.6 37.8 oral glucose tolerance test 0.0 oral glucose 30 min 110749 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 10 307.8 mg/dl 19.8 62.61 oral glucose tolerance test 0.0 oral glucose 60 min 110751 3183
GK/MolTac blood hemoglobin A1c level sham surgical control condition (for 126 days) then sodium bicarbonate (8.4 %) (for 112 days) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 224 days 9 5.5 % 0.3 0.9 blood hemoglobin analysis 0.0 sham surgery 105 days 110760 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 105 days 10 335.6 g 5.2 16.44 body weighing method 0.0 0 110730 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 105 days 8 325.4 g 9.2 26.02 body weighing method 0.0 0 110729 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 119 days 8 343.0 g 9.0 25.46 body weighing method 0.0 0 110735 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 119 days 9 median 113.4 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 7.9; 5.9 75%; 25% 110743 3183
GK/MolTac blood glucose level control condition Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 56 days 10 127.8 mg/dl 1.8 5.69 blood glucose analysis 0.0 0 110264 3168
GK/MolTac blood glucose level anti-rh-VEGF165 monoclonal antibody (1 mg) (for 14 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 70 days 10 131.4 mg/dl 7.2 22.77 blood glucose analysis 0.0 0 110268 3168
GK/MolTac body weight control condition Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 56 days 9 188.0 g 3.0 9.0 body weighing method 0.0 0 110243 3168
GK/MolTac body weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 14 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 70 days 10 212.0 g 5.0 15.81 body weighing method 0.0 0 110248 3168
GK/MolTac body weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 98 days 9 237.0 g 4.0 12.0 body weighing method 0.0 0 110255 3168
GK/MolTac food intake rate anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. eating behavior trait female 98 days 10 16.2 g/d 1.0 3.16 food intake measuring method 0.0 0 110260 3168
GK/MolTac ejection fraction control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 66.0 % 11.0 31.11 vascular transducer tipped catheter 0.0 0 102963 2783
GK/MolTac cardiac output control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 32.0 ml/min 6.0 16.97 vascular transducer tipped catheter 0.0 0 102965 2783
GK/MolTac stroke volume control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 65000.0 ml 11000.0 31112.7 vascular transducer tipped catheter 0.0 0 102969 2783
GK/MolTac red blood cell count sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 7 8.6 x 10E6 cells/ul 0.34 0.9 automated blood cell counting method 0.0 0 103842 2864
GK/MolTac red blood cell count sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 7 9.0 x 10E6 cells/ul 0.26 0.7 automated blood cell counting method 0.0 0 103845 2864
GK/MolTac red blood cell count rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 5 9.3 x 10E6 cells/ul 0.36 0.8 automated blood cell counting method 0.0 0 103849 2864
GK/MolTac blood hemoglobin level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 7 14.4 g/dl 0.6 1.6 automated hematology analysis 0.0 0 103853 2864
GK/MolTac blood hemoglobin level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 7 17.0 g/dl 0.19 0.5 automated hematology analysis 0.0 0 103859 2864
GK/MolTac hematocrit control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 6 42.3 % 3.8 9.3 automated hematology analysis 0.0 0 103864 2864
GK/MolTac hematocrit rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 7 54.1 % 0.83 2.2 automated hematology analysis 0.0 0 103871 2864
GK/MolTac hematocrit sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 7 58.1 % 0.6 1.6 automated hematology analysis 0.0 0 103872 2864
GK/MolTac blood hemoglobin A1c level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 6 4.75 % 0.06 0.14 automated hematology analysis 0.0 0 103876 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 5 5.2 % 0.1 0.22 automated hematology analysis 0.0 0 103882 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103821 2864
GK/MolTac whole body insulin sensitivity index fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 70 days-77 days 6 10,000/√(FG x FI) x (Ḡ x Ī) 1.94 null 0.1 0.24 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103825 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103824 2864
GK/MolTac whole body insulin sensitivity index rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 10,000/√(FG x FI) x (Ḡ x Ī) 1.72 null 0.3 0.59 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103828 2864
GK/MolTac whole body insulin sensitivity index rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 10,000/√(FG x FI) x (Ḡ x Ī) 2.04 null 0.21 0.42 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103831 2864
GK/MolTac whole body insulin sensitivity index rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 10,000/√(FG x FI) x (Ḡ x Ī) 1.27 null 0.23 0.46 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103830 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 3 (fasting glucose x fasting insulin)/22.5 9.8 null 1.21 2.1 oral glucose tolerance test 7200.0 0 103834 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 (fasting glucose x fasting insulin)/22.5 13.0 null 2.65 5.3 oral glucose tolerance test 7200.0 0 103836 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 (fasting glucose x fasting insulin)/22.5 10.2 null 1.35 2.7 oral glucose tolerance test 7200.0 0 103835 2864
GK/MolTac red blood cell count control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 6 6.6 x 10E6 cells/ul 0.57 1.4 automated blood cell counting method 0.0 0 103840 2864
GK/MolTac maximum rate of negative change in left ventricular blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 -12940.0 mmHg/s 1112.0 3145.21 vascular transducer tipped catheter 0.0 0 102979 2783
GK/MolTac body weight control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 6 382.0 g 13.0 31.84 body weighing method 0.0 0 103981 2885
GK/MolTac blood glucose level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 12 282.0 mg/dl 17.0 58.89 blood glucose analysis 0.0 0 103993 2885
GK/MolTac blood glucose level sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 122 days-129 days 4 162.0 mg/dl 14.0 28.0 oral glucose tolerance test 0.0 0 103808 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 70 days-77 days 6 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 120.0 0 measured at -5,15,30,45,60,90,120 min 103818 2864
GK/MolTac blood insulin level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 12 65.29 mU/l 8.82 30.57 blood insulin analysis 0.0 0 104001 2885
GK/MolTac blood insulin level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 6 51.18 mU/l 5.88 14.41 blood insulin analysis 0.0 0 104000 2885
GK/MolTac blood insulin level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 12 55.59 mU/l 5.0 17.32 blood insulin analysis 0.0 0 104002 2885
GK/MolTac blood malondialdehyde level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.7 umol/l 1.7 thiobarbituric acid assay 0.0 0 104015 2885
GK/MolTac blood malondialdehyde level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.0 umol/l 1.6 thiobarbituric acid assay 0.0 0 104016 2885
GK/MolTac body weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. body mass female 420 days 11 292.0 g 6.0 19.9 body weighing method 0.0 0 body weight 106895 3071
GK/MolTac food intake rate control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. eating behavior trait female 60 days 6 16.1 g/d 0.4 0.98 food intake measuring method 0.0 0 food consumption 106899 3071
GK/MolTac blood glucose level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 240 days 11 311.4 mg/dl 14.4 47.76 blood glucose test strip read by optical glucometer 0.0 0 fasting blood glucose, non fasting blood glucose 106906 3071
GK/MolTac serum insulin level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 60 days 6 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106923 3071
GK/MolTac systolic blood pressure control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. arterial blood pressure trait female 240 days 11 124.0 mmHg 3.0 9.95 tail cuff plethysmography 0.0 0 10 consecutive measurements 106930 3071
GK/MolTac both kidneys wet weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. kidney mass female 420 days 0 0.92 g 0.02 post excision weight measurement 0.0 0 kidney weight, kidney weight to body weight ratio 106939 3071
GK/MolTac heart wet weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. heart mass female 420 days 0 0.86 g 0.02 post excision weight measurement 0.0 0 106945 3071
GK/MolTac serum amylase activity level sham surgical control condition (for 126 days) then sodium bicarbonate (8.4 %) (for 112 days) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 252 days 9 2265.0 U/l 40.0 120.0 automated serum analysis 0.0 105 days 110763 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 8 253.8 mg/dl 16.2 45.82 oral glucose tolerance test 0.0 oral glucose 90 min 110753 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 112 days 10 352.4 g 6.5 20.55 body weighing method 0.0 0 110733 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 8 120.6 mg/dl 3.6 10.18 oral glucose tolerance test 0.0 oral glucose 0 min 110744 3183
GK/MolTac both kidneys wet weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 9 1.39 g 0.03 0.08 post excision weight measurement 0.0 0 110291 3168
GK/MolTac left kidney wet weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 10 0.69 g 0.02 0.05 post excision weight measurement 0.0 0 110288 3168
GK/MolTac liver weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. liver mass female 98 days 9 8.55 g 0.22 0.65 post excision weight measurement 0.0 0 110295 3168
GK/MolTac liver weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. liver mass female 98 days 10 8.24 g 0.36 1.15 post excision weight measurement 0.0 0 110296 3168
GK/MolTac blood glucose level anti-rh-VEGF165 monoclonal antibody (1 mg) (for 28 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 84 days 10 129.6 mg/dl 1.8 5.69 blood glucose analysis 0.0 0 110272 3168
GK/MolTac blood glucose level anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 98 days 10 115.2 mg/dl 1.8 5.69 blood glucose analysis 0.0 0 110276 3168
GK/MolTac blood glucose level control IgG monoclonal antibody (1 mg) (for 28 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 84 days 9 127.8 mg/dl 1.8 5.4 blood glucose analysis 0.0 0 110271 3168
GK/MolTac serum insulin level control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood insulin amount female 98 days 9 0.0 mg/dl 0.0 0.0 serum insulin analysis 0.0 0 110279 3168
GK/MolTac body weight control IgG monoclonal antibody (1 mg) (for 14 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 70 days 9 207.0 g 5.0 15.0 body weighing method 0.0 0 110247 3168
GK/MolTac body weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 28 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 84 days 10 235.0 g 5.0 15.81 body weighing method 0.0 0 110252 3168
GK/MolTac food intake rate control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. eating behavior trait female 98 days 9 15.8 g/d 0.9 2.7 food intake measuring method 0.0 0 110259 3168
GK/MolTac tissue mitochondrial DNA to nuclear DNA ratio control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. tissue DNA amount male 147 days 6 913.5 null 400.9 982.0 real-time polymerase chain reaction assay 0.0 0 tissue mitochondrial DNA to nuclear DNA ratio (CMO:0003889) 138274 2885
GK/MolTac urine norepinephrine level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. urine norepinephrine amount male 112 days 8 2743.0 nmol/l 883.0 2497.5 urine analysis 0.0 0 102953 2783
GK/MolTac heart rate control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart pumping trait male 112 days 8 476.0 beats/min 18.0 50.91 vascular transducer tipped catheter 0.0 0 102955 2783
GK/MolTac red blood cell count rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 7 9.4 x 10E6 cells/ul 0.08 0.2 automated blood cell counting method 0.0 0 103847 2864
GK/MolTac blood hemoglobin level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 6 13.1 g/dl 1.18 2.9 automated hematology analysis 0.0 0 103852 2864
GK/MolTac blood hemoglobin level control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 70 days-77 days 7 15.8 g/dl 0.34 0.9 automated hematology analysis 0.0 0 103851 2864
GK/MolTac hematocrit control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 7 46.0 % 2.0 5.3 automated hematology analysis 0.0 0 103865 2864
GK/MolTac hematocrit rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 122 days-129 days 5 53.4 % 1.25 2.8 automated hematology analysis 0.0 0 103870 2864
GK/MolTac blood hemoglobin A1c level sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 7 5.41 % 0.08 0.22 automated hematology analysis 0.0 0 103881 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 7 5.61 % 0.12 0.32 automated hematology analysis 0.0 0 103886 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 4 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103819 2864
GK/MolTac left ventricular diastolic blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricular blood pressure trait male 112 days 8 5.7 mmHg 0.4 1.13 vascular transducer tipped catheter 0.0 0 102985 2783
GK/MolTac body weight running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 0 366.0 g 6.0 body weighing method 0.0 0 103986 2885
GK/MolTac blood glucose level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 12 352.0 mg/dl 39.0 135.1 blood glucose analysis 0.0 0 103992 2885
GK/MolTac blood glucose level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 6 290.0 mg/dl 30.0 73.48 blood glucose analysis 0.0 0 103991 2885
GK/MolTac blood glucose level control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood glucose amount male 144 days 12 305.0 mg/dl 18.0 62.35 blood glucose analysis 0.0 0 103994 2885
GK/MolTac plasma insulin level rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 95 days-102 days 3 30.42 mU/l 4.2 7.28 oral glucose tolerance test 0.0 0 103813 2864
GK/MolTac blood dipeptidyl peptidase 4 activity level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 235.0 pmol/min 25.0 blood enzyme activity assay 0.0 0 104007 2885
GK/MolTac blood dipeptidyl peptidase 4 activity level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 192.0 pmol/min 4.0 blood enzyme activity assay 0.0 0 104010 2885
GK/MolTac plasma glucose level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood glucose amount male 112 days 8 223.2 mg/dl 32.4 91.64 automated plasma glucose analysis 0.0 0 102937 2783
GK/MolTac serum insulin level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood insulin amount male 112 days 8 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 102943 2783
GK/MolTac serum aldosterone level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood aldosterone amount male 112 days 8 3.63 nmol/l 0.91 2.59 radioimmunoassay 0.0 0 102945 2783
GK/MolTac body weight control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. body mass female 240 days 11 280.0 g 6.0 19.9 body weighing method 0.0 0 body weight 106894 3071
GK/MolTac food intake rate control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. eating behavior trait female 420 days 11 17.2 g/d 0.4 1.33 food intake measuring method 0.0 0 food consumption 106901 3071
GK/MolTac serum insulin level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 240 days 11 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106924 3071
GK/MolTac serum insulin level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood insulin amount female 420 days 11 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 fasting insulin, non fasting insulin 106925 3071
GK/MolTac systolic blood pressure control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. arterial blood pressure trait female 420 days 11 116.0 mmHg 1.7 5.64 tail cuff plethysmography 0.0 0 10 consecutive measurements 106931 3071
GK/MolTac kidney glomerulus basement membrane thickness control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. kidney glomerulus morphology trait female 420 days 0 337.0 nm 16.0 ex vivo electron microscopy with digital image analysis 0.0 0 kidney basement membrane thickness 106947 3071
GK/MolTac blood glucose level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 420 days 11 228.6 mg/dl 9.0 29.85 blood glucose test strip read by optical glucometer 0.0 0 fasting blood glucose, non fasting blood glucose 106913 3071
GK/MolTac body weight control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. body mass male 112 days 0 351.0 g 5.0 body weighing method 0.0 0 108025 3109
GK/MolTac mean arterial blood pressure control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. arterial blood pressure trait male 154 days 0 127.0 mmHg 4.0 tail cuff plethysmography 0.0 0 108033 3109
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 0.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 10 289.8 mg/dl 21.6 68.31 oral glucose tolerance test 0.0 oral glucose 30 min 110748 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 9 273.6 mg/dl 14.4 43.2 oral glucose tolerance test 0.0 oral glucose 60 min 110752 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 10 279.0 mg/dl 14.4 45.54 oral glucose tolerance test 0.0 oral glucose 90 min 110754 3183
GK/MolTac blood hemoglobin A1c level sleeve gastrectomy (for 126 days) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 224 days 10 4.8 % 0.3 0.95 automated blood analysis 0.0 105 days 110759 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 119 days 10 350.1 g 7.7 24.35 body weighing method 0.0 0 110736 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 112 days 9 median 126.0 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 9.0; 6.2 75%; 25% 110740 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 119 days 10 median 131.4 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 8.5; 6.1 75%; 25% 110742 3183
GK/MolTac left kidney wet weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 9 0.68 g 0.02 0.07 post excision weight measurement 0.0 0 110287 3168
GK/MolTac blood glucose level control IgG monoclonal antibody (1 mg) (for 14 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood glucose amount female 70 days 9 117.0 mg/dl 1.8 5.4 blood glucose analysis 0.0 0 110267 3168
GK/MolTac body weight control condition Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 56 days 10 191.0 g 3.0 9.49 body weighing method 0.0 0 110244 3168
GK/MolTac body weight control IgG monoclonal antibody (1 mg) (for 28 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 84 days 9 230.0 g 4.0 12.0 body weighing method 0.0 0 110251 3168
GK/MolTac right kidney wet weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 10 0.72 g 0.02 0.06 post excision weight measurement 0.0 0 110284 3168
GK/MolTac middle cerebral artery outer diameter control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. cerebral artery size trait male 154 days 20 215.0 um 10.0 44.72 ex vivo light microscopy with inverted microscope 0.0 0 with video image analysis 109092 3109
GK/MolTac mean arterial blood pressure control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. arterial blood pressure trait male 112 days 8 104.0 mmHg 5.0 14.14 vascular transducer tipped catheter 0.0 0 102961 2783
GK/MolTac cardiac index control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 97.0 ml/min/g 21.0 59.4 vascular transducer tipped catheter 0.0 0 102967 2783
GK/MolTac urine glucose level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. urine glucose amount male 112 days 8 86.0 mg/dl 31.0 87.68 urine analysis 0.0 0 102951 2783
GK/MolTac red blood cell count sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 164 days-171 days 7 9.8 x 10E6 cells/ul 0.3 0.8 automated blood cell counting method 0.0 0 103848 2864
GK/MolTac blood hemoglobin level rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 6 16.6 g/dl 0.2 0.5 automated hematology analysis 0.0 0 103855 2864
GK/MolTac blood hemoglobin level sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 122 days-129 days 7 16.2 g/dl 0.45 1.2 automated hematology analysis 0.0 0 103857 2864
GK/MolTac blood hemoglobin level sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 7 17.9 g/dl 0.15 0.4 automated hematology analysis 0.0 0 103860 2864
GK/MolTac blood hemoglobin level rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 7 17.8 g/dl 0.08 0.2 automated hematology analysis 0.0 0 103862 2864
GK/MolTac hematocrit sodium chloride solution (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 95 days-102 days 7 51.1 % 2.8 7.4 automated hematology analysis 0.0 0 103866 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 95 days-102 days 6 4.95 % 0.06 0.15 automated hematology analysis 0.0 0 103879 2864
GK/MolTac blood hemoglobin A1c level rosiglitazone (5 mg/kg) (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 7 5.86 % 0.24 0.64 automated hematology analysis 0.0 0 103885 2864
GK/MolTac blood hemoglobin A1c level sodium chloride solution (for 23 days) then control condition (for 60 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood hemoglobin amount male 164 days-171 days 7 6.89 % 0.61 1.61 automated hematology analysis 0.0 0 103884 2864
GK/MolTac blood glucose level rosiglitazone (5 mg/kg) (for 23 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 95 days-102 days 3 146.0 mg/dl 3.46 6.0 oral glucose tolerance test 0.0 0 103806 2864
GK/MolTac blood glucose level rosiglitazone (10 mg/kg) (for 23 days) then fasting (for 16 hours) then glucose solution (2 g/kg) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood glucose amount male 95 days-102 days 4 142.0 mg/dl 4.0 8.0 oral glucose tolerance test 0.0 0 103807 2864
GK/MolTac blood insulin level AUC to blood glucose level AUC ratio sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 AUC ins/glu 0.0 null 0.0 0.0 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103822 2864
GK/MolTac whole body insulin sensitivity index sodium chloride solution (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 10,000/√(FG x FI) x (Ḡ x Ī) 1.49 null 0.31 0.62 oral glucose tolerance test 7200.0 0 measured at -5,15,30,45,60,90,120 min 103829 2864
GK/MolTac Homeostatic Model Assessment of Insulin Resistance rosiglitazone (10 mg/kg) (for 23 days) then control condition (for 20 days) then fasting (for 12 hours) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. blood insulin amount male 122 days-129 days 4 (fasting glucose x fasting insulin)/22.5 8.2 null 1.35 2.7 oral glucose tolerance test 7200.0 0 103838 2864
GK/MolTac red blood cell count control condition (between 70 and 77 days) Gao W and Jusko WJ, J Pharmacol Exp Ther. 2012 Jun;341(3):617-25. doi: 10.1124/jpet.112.192419. Epub 2012 Feb 29. erythrocyte quantity male 70 days-77 days 7 7.8 x 10E6 cells/ul 0.15 0.4 automated blood cell counting method 0.0 0 103839 2864
GK/MolTac preload recruitable left ventricle stroke work control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. cardiac output trait male 112 days 8 73.0 mmHg 6.0 16.97 vascular transducer tipped catheter 0.0 0 102983 2783
GK/MolTac heart left ventricle end-diastolic anterior wall index control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricle anterior wall thickness male 112 days 8 7.31 mm/kg 0.22 0.62 echocardiography 0.0 0 102994 2783
GK/MolTac heart left ventricle end-diastolic diameter to body weight ratio control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. heart left ventricle diameter male 112 days 8 15.29 mm/kg 0.51 1.44 echocardiography 0.0 0 102996 2783
GK/MolTac body weight running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. body mass male 147 days 6 373.0 g 5.0 12.25 body weighing method 0.0 0 103982 2885
GK/MolTac blood insulin level control condition Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 6 57.65 mU/l 11.47 28.1 blood insulin analysis 0.0 0 103999 2885
GK/MolTac blood insulin level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood insulin amount male 147 days 12 58.24 mU/l 5.88 20.38 blood insulin analysis 0.0 0 104004 2885
GK/MolTac blood dipeptidyl peptidase 4 activity level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 192.0 pmol/min 4.0 blood enzyme activity assay 0.0 0 104008 2885
GK/MolTac blood dipeptidyl peptidase 4 activity level running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood enzyme amount male 147 days 0 88.0 pmol/min 21.0 blood enzyme activity assay 0.0 0 104012 2885
GK/MolTac blood malondialdehyde level control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. blood malondialdehyde amount male 147 days 0 6.5 umol/l 1.0 thiobarbituric acid assay 0.0 0 104019 2885
GK/MolTac plasma total cholesterol level control condition Korkmaz-Ic�z S, et al., Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H958-H971. doi: 10.1152/ajpheart.00956.2015. Epub 2016 Aug 12. blood cholesterol amount male 112 days 8 96.0 mg/dl 7.0 19.8 automated plasma total cholesterol analysis 0.0 0 102939 2783
GK/MolTac blood glucose level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 60 days 6 268.2 mg/dl 14.4 35.27 blood glucose test strip read by optical glucometer 0.0 0 tail vein blood fasting blood glucose, non fasting blood glucose 106905 3071
GK/MolTac both kidneys wet weight to body weight ratio control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. kidney mass female 420 days 0 3.14 g/kg 0.07 post excision weight measurement 0.0 0 kidney weight, kidney weight to body weight ratio 106953 3071
GK/MolTac systolic blood pressure control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. arterial blood pressure trait female 60 days 6 114.0 mmHg 0.09 0.22 tail cuff plethysmography 0.0 0 10 consecutive measurements 106929 3071
GK/MolTac blood glucose level fasting (for 6 hours) Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood glucose amount female 240 days 11 172.8 mg/dl 10.8 35.82 blood glucose test strip read by optical glucometer 0.0 0 fasting blood glucose, non fasting blood glucose 106912 3071
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 0.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 8 250.2 mg/dl 21.6 61.09 oral glucose tolerance test 0.0 oral glucose 30 min 110747 3183
GK/MolTac body weight control condition Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. body mass male 154 days 0 419.0 g 7.0 body weighing method 0.0 0 108027 3109
GK/MolTac serum insulin level anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. blood insulin amount female 98 days 10 0.0 mg/dl 0.0 0.0 serum insulin analysis 0.0 0 110280 3168
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 1.5 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 9 244.8 mg/dl 12.6 37.8 oral glucose tolerance test 0.0 oral glucose 90 min 110755 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) then glucose (for 2 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 105 days 10 234.0 mg/dl 9.0 28.46 oral glucose tolerance test 0.0 oral glucose 120 min 110757 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 112 days 9 345.8 g 8.4 25.2 body weighing method 0.0 0 110734 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 112 days 8 337.1 g 9.3 26.3 body weighing method 0.0 0 110732 3183
GK/MolTac body weight control condition Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. body mass male 119 days 9 350.8 g 9.8 29.4 body weighing method 0.0 0 110737 3183
GK/MolTac blood glucose level fasting (between 14 and 18 hours) Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. blood glucose amount male 112 days 10 median 126.0 mg/dl blood glucose test strip read by electrochemical glucometer 0.0 0 7.3; 6.2 75%; 25% 110739 3183
GK/MolTac right kidney wet weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 9 0.71 g 0.01 0.03 post excision weight measurement 0.0 0 110283 3168
GK/MolTac heart weight control IgG monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. heart mass female 98 days 9 0.74 g 0.02 0.05 post excision weight measurement 0.0 0 110299 3168
GK/MolTac body weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. body mass female 98 days 10 241.0 g 5.0 15.81 body weighing method 0.0 0 110256 3168
GK/MolTac both kidneys wet weight anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. kidney mass female 98 days 10 1.42 g 0.03 0.1 post excision weight measurement 0.0 0 110292 3168
GK/MolTac serum 8-epi-prostaglandin F2alpha level control condition Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. blood eicosanoid amount female 0 days 11 973.0 ng/l 243.0 805.94 enzyme immunoassay 0.0 0 blood 8-epi-prostaglandin F2alpha amount 108087 3071